Modern approaches to the treatment of osteoarthritis

The data given in the article is in accordance with the latest recommendations of ESCEO years 2016, 2019 in regard to possibilities of the sympthom-modifying and structure-modifying action of chondroitin sulfate in the treatment of patients with osteoarthritis. There is the data on the therapy effect when treating patients with osteoarthritis and with periarticular tissues damage with chondroitin sulfate injections (Alflutop, Biotehnos) having strong evidence base, including randomized placebo-controlled studies. In the randomized study it is shown reliably high effectiveness of Alflutop against placebo in regard to main clinical manifestations of the desease as well as possibility to slow down progress of the destructive processes at osteoarthritis of the knee-joint. The data given on estimation of effectiveness and safety of alternate introduction of Alflutop at osteoarthritis 2 ml intramuscularly every other day (10 injections) compared with a standard mode of use of Alflutop 1 ml intramuscularly every day for 20 days. Equal effectiveness of the two modes of Alflutop introduction is demonstrated subject to good tolerance of the drug. Ability of Alflutop to supress the mediators of inflammation, such as interleukins 6 and 8, and degradations at osteoarthritis, as well as to stimulate the proliferation and renewal of chondrocytes is shown according to the results of an international experimental study, explaining its ability to cause a quick analgesic and anti-inflammatory effect. Alflutop inhibits in vitro extracellular release of the pro-inflammatory cytokine interleukin 6 (IL-6) for 16 per cent and chemokine IL-8 for 35 per cent, inhibits pro-angiogenic factor VEGF for 56 per cent, has an antioxidant effect, which contributes to the synthesis of cartilage macromolecules, a decrease in the activity of matrix metalloproteases (MMPs), a decrease in the concentration of prostaglandins and leukotrienes, and a decrease in chondrocyte apoptosis. The data on the effectiveness of the Alflutop injection course in case of damage to the periaticular tissues in the shoulder, elbow, knee joint is given. The data on the gastroprotective effect of the drug, demonstrated in experimental and clinical studies is given.

1. Musumeci G., Aiello F.C., Szychlinska M.A., Di Rosa V., Gastrogiovanni P., Mobasheri A. Osteoarthritis in the XXIst century: risk factors and behaviors that influence disease onset and progression. Int J Mol Sci. 2015;16(3):6093-6112. doi: 10.3390/ijms16036093.

2. Galushko E.A., Bolshakova T.Y., Vinogradova I.B., Ivanova O.N., Lesnyak O.M., Menshikova L.V. et al. Structure of rheumatic diseases among adult population of Russia according to data of an epidemiological study (preliminary results). Nauchno-prakticheskaya revmatologiya = Rheumatology Science and Practice. 2009;47(1):11-17. (In Russ.) doi: 10.14412/1995-4484-2009-136.

3. Erdes S.F., Folomeeva O.M. Rheumatic diseases and disability of Russian Federation adult population. Nauchno-prakticheskaya revmatologiya = Rheumatology Science and Practice. 2007;45(4):4-9. (In Russ.) doi: 10.14412/1995-4484-2007-4-9.

4. Loeuille D., Chary-Valckenaere I., Champigneulle J., Rat A.C., Toussant F., Pinzano-Watrin A. et al. Macroscopic and microscopic features of synovial membrane inflammation in the osteoarthritic knee: correlating magnetic resonance imaging findings with disease severity. Arthritis Rheum. 2005;52(11):3492-3501. doi: 10.1002/art.21373.

5. Sellman J., Berenbaum F. The role of synovitis in pathophysiology and clinical symptoms of osteoarthritis. Nat Rev Rheumatol. 2010;6(11):625-635. doi: 10.1038/nrrheum.2010.159.

6. Chen Y., Jiang W., Yong H., He M., Yang Y., Deng Z., Li Y. Macrophages in osteoarthritis: pathophysiology and therapeutics. Am J Trans Res. 2020;12(1):261-268. Available at: https//www.ncbi.nlm.nih.gov/pmc/articles/PMC7013211/.

7. van Dijk G.V., Veenhof C., Schelleviset S., Hulsmans H., Bakker J.P., Arwert H. et al. Comorbidity, limitations in activities and pain in patients with osteoarthritis of the hip or knee. BMC Musculoskelet Disord. 2008;9:95. doi: 10.1186/1471-2474-9-95.

8. Caporali R., Cimmino M.A., Sarzi-Puttini P., Scarpa R., Parazini F., Zanneli A. et al. Comorbid conditions in the AMICA study patients: effect on the quality of life and drug prescriptions by general practitioners and specialists. Seminaris Arthritis Rheum. 2005;35(1):31-37. doi: 0.1016/j.semar-thrit.2005.02.004.

9. McAlindon T.E., Bannuru R.R., Sullivan M.C., Arden N.K., Berenbaum F., Bierma-Zeinstra S.M. et al. OARSI Guidelines for the non-surgical management of knee osteoarthritis. Ostearthr Cartilage. 2014;22(3):363-388. doi: 10.1016/j.joca.2014.01.003.

10. Wills A.K., Black R., Cooper R., Coppack R.J., Hardy R., Remmes M.K. et al. Life course body mass index and risk of knee osteoarthritis at the age of 53 years: evidence from 1946 British cohort study. Ann Rheum Dis. 2012;71(5):655-660. doi: 10.1136/ard.2011.154021.

11. Scherzer Z.A., Alvarez C., Penner J.B., Murphy L.B., Schwartz T.A., Jordan J.M. et al. Effect of comorbid cardiovascular disease and diabetes mellitus on hand osteoarthritis, pain and functional state transitions. J Rheumatol. 2020. pii: jrheum.191075. doi: 10.3899/jrheum.191075.

12. Alenazi A.M., Alothman S., Alshehri M.M., Rucker J., Waltman L.R., Wick J. et al. The prevalence of type 2 diabetes and associated risk factors with generalized osteoarthritis: a retrospective study using ICD codes for clinical data repository system. Clin Rheum. 2019;38(12):3559-3547. doi: 10.1007/s10067-019-04712-0.

13. Berenbaum F., Grifftin T.M., Liu-Bryan R. Metabolic regulation of inflammation in osteoarthritis. Arthr Rheum. 2017;69(1):9-21. doi: 10.1002/art.39842.

14. Schett G., Kleyer A., Perricone C., Sahinbegovic E., Iagnocco A., Zwerina J. et al. Diabetes is an independent predictor for severe osteoarthritis: results from a longitudinal cohort study. Diabetes care. 2013;36(2):403-409. doi: 10.2337/dc12-0924.

15. Le Clanche S., Bonnefont-Rousselot D., Sari-Ali E., Rannou F., Borderie D. Inter-relations between osteoarthritis and metabolic syndrome: A common link? Biochemie. 2016;121(12):238-252. doi: 10.1016/j.bio-chi.2015.12.008.

16. Dubey N.K., Ningrum D.N.A., Dubey R., Deng Y.-H., Li Y.-C., Wang P.D. et. al. Correlation between Diabetes Mellitus and Knee Osteoarthritis: A Dry-To-Wet Lab Approach. Int J Mol Sci. 2018;19(10):3021. doi: 10.3390/ijms19103021.

17. Yoshimura N., Muraki S., Oka H., Tanaka S., Kawaguchi H., Nakamura K., Akune T. Accumulation of metabolic risk factors such as overweight, hypertension, dislipidemia and impaired glucose tolerance raises the risk of occurrence and progression of knee osteoarthritis: a 3-year follow-up of the ROAD study. Osteoarthritis Cartilage. 2012;20(11):1217-1226. doi: 10.1016/j.joca.2012.06.006.

18. Courties A., Berenbaum F., Sellam J. The phenotypic approach to osteoarthritis: a look at metabolic-associated osteoarthritis. Joint Bone Spine. 2019;86(6):725-730. doi: 10.1016/j.jbspin.2018.12.005.

19. Yoshimura N., Muraki S., Nakamura K., Tanaka S. Epidemiology of the locomotive syndrome: the research on osteoarthritis/osteoporosis against disability study 2000-2015. Mod Rheumatol. 2017;27(1):1-7. doi: 10.1080/14397595.2016.1226471.

20. Strand M.P., Neogi T., Nin J., Felson D.T., Haugen I.K. Association between metabolic syndrome and radiographic hand osteoarthritis: data from a community-based longitudinal cohort study. Arthr Care Res. 2018;70(3):469-474. doi: 10.1002/acr.23288.

21. Marshall M., Peat G., Nochoels E., Mayers H.L., Mamas M.A., der Windt D.A. Metabolic risk factors and the incidence and progression of radiographic hand osteoarthritis: a population-based cohort study. Scand J Rheumatol. 2019;48(1):52-63. doi: 10.1080/03009742.2018.1459831.

22. Eymard F., Parsons C., Edwards M.H., Petit-Dop F., Reginster J.-Y., Bruyere O. et al. Diabetes is a risk factor for knee osteoarthritis progression. Osteoarthritis Cartilage. 2015;23(6):851-859. doi: 10.1016/j.joca.2015.01.013.

23. Roberts E., Delgado Nunes V., Buckner S., Latchem S., Constanti M., Miller P. Paracetamol: not safe as we thought? A systematic review of observational studies. Ann Rheum Dis. 2016;75(3):552-559. doi: 10.1136/ann-rheumdis-2014-206914.

24. Bruyere O., Cooper C., Pelletier J.-P., Maheu E., Rannou F., Branco J. et al. A consensus statement on the European Society for clinical and economic aspects of osteoporosis and osteoarthritis (ESCEO) algorithm for the management of knee osteoarthritis - from evidence-based medicine to the real-life setting. Sem Arthr Reum. 2016;45(4 Suppl):S3-S11. doi: 10.1016/j.semarthrit.2015.11.010.

25. Bruyere O., Honvo G., Veronese N., Arden N.K., Branco J., Curtis E.M. et.al. An updated algorithm recommendation for the management of knee osteoarthritis from the European Society for Clinical and Economic aspe-crs of Osteoporosis, Osteoarthritis and Musculoskeletal diseases (ESCEO). Sem Arthr Rheum. 2019;49(3):337-350. doi: 10.1016/j.semar-thrit.2019.04.008.

26. Karateev A.E., Nasonov E.L., Ivashkin V.T., Martynov A.I., Yakhno N.N., Arutyunov G.P. et al. Rational use of nonsteroidal anti-inflammatory drugs. Clinical guidelines. Nauchno-prakticheskaya revmatologiya = Rheumatology Science and Practice. 2018;56:1-29. (In Russ.) doi: 10.14412/1995-44842018-1-29.

27. Simmental-Mendia M., Sauchez-Garcia A., Vilchez-Cavazos F., Acosta-Olivo C.A., Pena-Martinez V.M., Simental-Mend^a L.E. Effect of glucosamine and chondroitin sulfate in symptomatic knee osteoarthritis: a systematic review and meta-analysis of randomized placebo-controlled trials. Rheumatol Int. 2018,38(8):1413-1428. doi: 10.1007/s00296-018-4077-2.

28. Gregori D., Giacovelli G., Minto C., Barbetta B., Gualtieri F., Azzolina D. et al. Association of pharmacological treatments with long-term pain control in patients with knee osteoarthritis; a systematic review and meta-analysis. JAMA. 2018;320(24):2564-2579. doi: 10.1001/jama.2018.19319.

29. Leeb B.F., Schweitzer H., Montag K., Smolen J.S. A metaanalysis of chondroitin sulfate in the treatment of osteoarthritis. J Rheumatol. 2000;27(1):205-211. Available at: https://www.ncbi.nlm.nih.gov/pub-med/10648040.

30. Singh J.A., Noorbaloochi S., MacDonald R., Maxwell J. Chondroitin for osteoarthritis. Cochrane Database Syst Rev. 2015;(1):CD005614. doi: 10.1002/14651858.CD005614.pub2.

31. Honvo G., Bruyere O., Geerinck A., Veronese N., Reginster J.Y. Efficacy of chondroitin sulfate in patients with knee osteoarthritis: a comprehensive meta-analysis exploring inconsistencies in randomized, placebo-controlled trials. Adv Ther. 2019;36(5):1085-1099. doi: 10.1007/s12325-019-00921-w.

32. Honvo G., Reginster J.Y., Rabenda V., Geerinck A., Mkinsi O., Rizzoli R. et. al. Safety of symptomatic slowacting drugs for osteoarthritis: outcomes of a systematic review and meta-analysis. Drug Aging. 2019;36(Suppl. 1):65-69. doi: 10.1007/s40266-019-00662-z.

33. Li J.H., Woo J.H., Choi S.J., Li J.D., Song G.G. Effect of glucosamine or chondroitin sulfate on the osteoarthritis progression: a meta-analysis. Reumatol Int. 2010;30(3):357-363. doi: 10.1007/s00296-009-0969-5.

34. Martel-Pellitier J., Roubille C., Abram F., Hochberg M.C., Dorais M., Delorme P. et al. First-line analysis on the effects of treatment on progression of structural changes in knee osteoarthritis over 24 months; data from the osteoarthritis initiative progression cohort. Ann Rheum Dis. 2015;74(3):547-556. doi: 10.1136/annrheumdis-2013-203906.

35. Levin O.S., Olyunin D.Y., Golubeva L.V. Alflutop efficacy in chronic vertebrogenous lumbar ischialgia. A double blind placebo controlled study. Nauchno-prakticheskaya revmatologiya = Rheumatology Science and Practice. 2004;42(4):80-84. (In Russ.) doi: 10.14412/1995-4484-2004-809.

36. Alekseeva L.I., Sharapova E.P., Taskina E.A., Chichasova N.V., Imametdinova G.R., Shostak N.A. et al. Multicenter double-blind randomized placebo-controlled trial of the symptom- and structure-modifying effect of alflutop in patients with knee osteoarthrosis. Communication 1. Evaluation of the symptom-modifying effect of the drug. Nauchno-prakticheskaya revmatologiya = Rheumatology Science and Practice. 2013;51(5):532-538. (In Russ.) doi: 10.14412/1995-4484-2013-1545.

37. Lukina G.V., Sigidin J.A., Chichasova N.V., Imametdinova G.R., Lobzanidse T.B., Pushkova O.V. et al. Alflutop in osteoarthritis therapy. Nauchno-prakticheskaya revmatologiya = Rheumatology Science and Practice. 2004;42(3):52-54. (In Russ.) doi: 10.14412/1995-4484-2004-1481.

38. Svetlova M.S., Ignat'ev V.K. Use of alflutop in the treatment of patients with osteoarthrosis. Klinicheskaya meditsina = Clinical Medicine (Russian Journal). 2004;82(6):52-55. (In Russ.) Available at: https://elibrary.ru/item.asp?id=17075545.

39. Chichasova N.V. Modern osteoarthritis therapy: alflutop in clinical practice, experimental and clinical data. Meditsinskiy sovet = Medical Council. 2017;(17):138-145. (In Russ.) doi: 10.21518/2079-701X-2017-17-138-145.

40. Alekseeva L.I., Sharapova E.P., Taskina E.A., Chichasova N.V., Imametdinova G.R., Shostak N.A. et al. A multicenter, blind, randomized, placebo-controlled study of the symptom- and structure-modifying effet of alflutop in patients with knee osteoarthritis. Report 2: the assessment of the structure-modifying effect of the drug. Nauchno-prakticheskaya revmatologiya = Rheumatology Science and Practice. 2014;52(2):174-177. (In Russ.) doi: 10.14412/1995-4484-2014-174-177.

41. Kuksgauz I.A., Shekunova E.V., Kashkin V.A., Faustova N.M., Guschin Ya.A., Makarova M.N., Makarov V.G. Gastroprotective eff ect of Alflutop on diclofenac-induced gastropathy in rats. Eksperimental'naya i klinicheskaya gastroen-terologiya = Experimental and Clinical Gastroenterology. 2019;166(5): 15-21. (In Russ.) doi: 10.31146/1682-8658-ecg-165-5-15-21.

42. Drozdov V.N., Kolomiec E.V. Application of Alflutop in patients with osteoarthritis and gastropathy developed against the background of NSAIDs treatment. Farmateka = Pharmateca. 2005;(20):125-128. (In Russ.) Available at: https://pharmateca.ru/ru/archive/article/6388.

43. Khitrov N.A. Local injection therapy of damage of paraarticular tissue. Khirurgiya. Zhurnal imeni N.I. Pirogova = Pirogov Russian Journal of Surgery. 2017;(11):44-50. (In Russ.) doi: 10.17116/hirurgia20171144-50.

44. Salikhov I.G., Volkova E.R., Yakupova S.P. Periarticular application of chondroprotectors in patients with gonarthrosis and signs of tendon-ligament apparatus injury. Consilium Medicum. 2006;8(2):50-53. (In Russ.) Available at: http://old.consilium-medicum.com/media/consilium/06_02/50.shtml.

45. Alekseeva L.I., Taskina E.A., Lila A.M., Mazurov V.I., Shostak N.A., Shmidt E.I., Ilivanova E.P. A multicenter, prospective, randomized trial of the efficacy and safety of Alflutop® in an alternating dosing regimen versus the standard one. Communication 1: Evaluation of the efficacy of the drug in different treatment regimens. Sovremennaya revmatologiya = Modern Rheumatology Journal. 2019;13(3):51-59. (In Russ.) doi: 10.14412/19967012-2019-3-51-59.

46. Henrotin Y., Marty M., Mobasheri A. What is the current status of chondroitin sulfate and glucosamine for the treatment of knee osteoarthritis. Maturitas. 2014;78(3):184-187. doi: 10.1016/j.maturitas.2014.04.015.

47. Hochberg M., Chevalier X., Henroitin Y., Hunter D.J., Uebelhart D. Symptom and structure modification in osteoarthritis with pharmaceutical-grade chondroitin sulfate: what's the evidence? Curr Med Res Opin. 2013;29(3):259-267. doi: 10.1185/03007995.2012.753430.

48. Monfort J., Pelletier J.P., Garcia-Giralt N., Martel-Pelletier J. Biochemical basis of the effect of chondroitin sulfate on a osteoarthritis articular tissues. Ann Rheum Dis. 2008;67(6):735-740. doi: 10.1136/ard.2006.068882.

49. Knopic J.J., Pope R., Hoedebecke S.S., Schram B., Orr R. Effect of oral chondroitin sulfate on osteoarthritic-related pain and joint structural changes: systematic review and meta-analysis. J Spec Oper Med. 2019;19(1):113-124. Available at: https://www.ncbi.nlm.nih.gov/pub-med/30859538.

50. Galagher B., Tjoumakaris F.P., Harwood M.I., Good R.P., Ciccotti M.G., Freedman K.B. Chondroprotection and prevention of osteoarthritis progression of the knee: a systematic review of treatment agents. Am J Sports Med. 2015;43(3):734-744. doi: 10.1177/0363546514533777.

51. Blanco F.J., Camacho-Encina M., Gonzalez-Rodriguea L., Mateos J., Fernandez-Puente P., Lourido L. et. al. Predictive modeling of therapeutic response to chondroitin culfate / glucosamine hydrochloride in the knee osteoarthritis. Ther Adv Chronic Dis. 2019;10(8):1-12. doi: 10.1177/2040622319870013.

52. Martel-Pelletier J., Raynald J.P., Mineau F., Abram F., Paiement P., Delorme P., Pelletier J-P. Levels of serum biomarkers from a two-year multicenter trial are associated with treatment response on knee osteoarthritis cartilage loss assessed by magnetic resonance imaging: an exploratory study. Arthritis Res Ther. 2017;19(1):169. doi: 10.1186/s13075-017-1377-y.

53. Kloppenburg M., Kroon F.P., Blanco F.J., Doherty M., Dziedzic K.S., Greibrokk I. et al. 2018 update of the EULAR recommendations for the management of hand osteoarthritis. Ann Rheum Dis. 2019;78(1):16-24. doi: 10.1136/annrheumdis-2018-213826.

54. Kolasinski S.L., Neogi T., Hochberg M.C., Oatis C., Guyatt G., Block J. et.al. 2019 American College of Rheumatology/Arthritis Foundation guidline for the management of osteoarthritis of the hand, hip, and knee. Arthritis Rheumatol. 2020;72(2):220-233. doi: 10.1002/art.41142.